PKPD and disease modeling: Concepts and applications to oncology

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 2011, Issue 1, 2011, Pages 281-310

  Della Pasqua, Oscar E ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CYTOSTATIC AGENT; CYTOTOXIC AGENT; MONOCLONAL ANTIBODY; PACLITAXEL; TRABECTEDIN; CHORIONIC GONADOTROPIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; INDISULAM; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OROSOMUCOID; RITUXIMAB;

ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RESEARCH; CLINICAL DECISION MAKING; COLORECTAL CANCER; COMPARTMENT MODEL; DISEASE COURSE; DISEASE MODEL; DOSE CALCULATION; DRUG DEVELOPMENT; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL MODEL; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; NEUTROPENIA; NONHUMAN; ONCOLOGY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIMULATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CANCER PROGNOSIS; DRUG BLOOD LEVEL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; PHARMACODYNAMICS; PHARMACOKINETICS; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME;

EID: 85081147738     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7415-0_13     Document Type: Article

References (99)

1. Agoram B, Heatherington AC, Gastonguay MR (2006) Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J 8(3):E552-E563.
2. Alfieri R, Merelli I, Mosca E, Milanesi L (2007) A data integration approach for cell cycle analysis oriented to model simulation in systems biology. BMC Syst Biol. doi:10.1186/1752-0509-1-35.
3. Bajzer Z, Marusic M, Vuk-Pavlocic S (1996) Conceptual frameworks for mathematical modeling of tumor growth dynamics. Math Comput Model 23:31-46.
4. Bellmunt J, Carles J, Albanell J (2009) Predictive modelling in hormone-refractory prostate cancer (HRPC). Clin Translat Oncol 11:82-85.
5. Brekelmans CT, Seynaeve C, Menke-Pluymers M, Brüggenwirth HT, Tilanus-Linthorst MM, Bartels CC, Kriege M, van Geel AN, Crepin CM, Blom JC, Meijers-Heijboer H, Klijn JG (2006) Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17:391-400.
6. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG (2007) Tumor characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43:867-876.
7. Bruggeman FJ, Westerhoff HV (2006) Approaches to biosimulation of cellular processes. J Biol Phys 32:273-288.
8. Bruno R, Claret L (2009) On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies. Clin Pharmacol Ther 86(2):136-138.
9. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 63(6):1035-1048.
10. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, L̈uck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran AG, Therasse P (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987-1992.
11. Buyse M (2009) Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer J 15:421-425.
12. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A (2010) Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 7(6):309-317.
13. Cameron DA, Gregory WM, Bowman A, Leonard RC (1996) Mathematical modelling of tumor response in primary breast cancer. Br J Cancer 73(11):1409-1416.
14. Cappuccio A, Castiglione F, Piccoli B (2007) Determination of the optimal therapeutic protocols in cancer immunotherapy. Mathl Biosci 209:1-13.
15. Chen LL, Blumm N, Christakis NA, Barabási AL, Deisboeck TS (2009) Cancer metastasis networks and the prediction of progression patterns. Br J Cancer 101:749-758.
16. Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R (2009) Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 27(25):4103-4108.
17. Coates JM, Galante JM, Bold RJ (2009) Cancer therapy beyond apoptosis: Autophagy and anoikis as mechanisms of cell death. J Surg Res. doi:10.1016/j.jss.2009.07.011.
18. Collins VP, Loeffler RK, Tivey H (1956) Observations on growth rates of human tumors. Am J Roetgenol Radium Ther Nucl Med 76:988-1000.
19. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G (2005) Mechanism-based pharmacokinetic- pharmacodynamic modeling-a new classification of biomarkers. Pharm Res 22 (9):1432-1437.
20. Daydé D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, Le Pape A, Bardos P, Paintaud G, Cartron G (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic- pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113(16):3765-3772.
21. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478
22. Dehing-Oberije C, Yu S, De Ruysscher D, Meersschout S, Van Beek K, Lievens Y, Van Meerbeeck J, De Neve W, Rao B, van der Weide H, Lambin P (2009) Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 74(2):355-362
23. Deisboeck T (2001) Pattern of self-organization in tumor systems: complex growth dynamics in a novel brain tumor spheroid model. Cell Prolif 34:115-134
24. Della Pasqua O, Santen GW, Danhof M (2010) The missing link between clinical endpoints and drug targets in depression. Trends Pharmacol Sci 31:144-152
25. Diva U, Banerjee S, Dey DK (2007) Modelling spatially correlated survival data for individuals with multiple cancers. Stat Modelling 7:191-213
26. Dormer P, Lau B, Wilmanns W (1980) Kinetics of bone marrow cell production in human acute and chronic myeloid leukemias. Leuk Res 4:231-237
27. European Medicines Agency. Committee for Medicinal Products for Human Use (2006) Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man (CHMP/ewp/ 205/95 rev.3). Methodological considerations for using progression-free survival (PFS) as primary endpoint in confirmatory trials for registration. http://www.emea.europa.eu/pdfs/human/ewp/26757506en.pdf
28. Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR (2008) Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res 14(18):5856-5863
29. Fidler IJ (2002) Critical determinants of metastasis. Semin Cancer Biol 12(2):89-96
30. Fleischer F, Gaschler-Markefski B, Bluhmki E (2009) A statistical model for the dependence between progression-free survival and overall survival. Stat Med 28:2669-2686
31. Frame D (2007) New strategies in controlling drug resistance in chronic myeloid leukemia. Am J Health Syst Pharm 64:S16-S21
32. Friberg LE, Karlsson MO (2003) Mechanistic models for myelosuppression. Invest New Drugs 21:183-194
33. Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ (2000) Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC). Eur J Clin Pharmacol 56:567-574
34. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapyinduced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721
35. Friberg LE, de Greef R, Kerbusch T, Karlsson MO (2009) Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 86(1):84-91
36. Gardner SN (2000) A mechanistic, predictive model of dose-response curves for cell cycle phasespecific and -nonspecific drugs. Cancer Res 60:1417-1425
37. Gasparini G, Biganzoli E, Bonoldi E, Morabito A, Fanelli A, Boracchi P (2001) Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Res Treat 65:71-75
38. Gieschke R, Burger HU, Reigner B, Blesch KS, Steimer JL (2003) Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 55:252-263
39. Gilbert D, Fuss H, Gu X, Orton R, Robinson S, Vyshemirsky V, Kurth MJ, Downes CS, Dubitzky W (2006) Computational methodologies for modelling, analysis and simulation of signalling networks. Brief Bioinform 7:339-353
40. Goel G, Chou IC, Voit EO (2006) Biological systems modeling and analysis: a biomolecular technique of the twenty-first century. J Biomol Tech 17:252-269
41. Goggin T, Nguyen QT, Munafo A (2004) Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer. Br J Clin Pharmacol 57(5):576-585
42. Harpold HL, Alvord EC Jr, Swanson KR (2007) The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol 66:1-9
43. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821-1828
44. Hénin E, Zuideveld KP, Dartois C, Tranchand B, Freyer G, Girard P (2006) A KPD model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine PAGE 15 (2006) Abstract 929. www.page-meeting.org/?abstract1/4929
45. Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, Zannikos P (2008) Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia. Clin Pharmacol Ther 83:130-143
46. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J (2006) Cancer: a Systems Biology disease. Biosystems 83:81-90
47. Howard A, Pelc SR (1951) Nuclear incorporation of P-32 as demonstrated by autoradiographs. Exp Cell Res 2:178-187
48. Jacqmin P, McFadyen L, Wade JR (2010) Basic PK/PD principles of drug effects in circular/ proliferative systems for disease modelling. J Pharmacokinet Pharmacodyn 37(2):157-177
49. Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Fety R, van derVijgh WF, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AHGL, Twelves C, Beijnen JH, Schellens JHM (2007a) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13:6410-6418
50. Joerger M, Huitema AD, Richel DJ et al (2007b) Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 46:1051-1068
51. Johnson JR, Williams G, Pazdur R (2003) Endpoints and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411
52. Klein JP (2006) Modelling competing risks in cancer studies. Stat Med 25:1015-1034
53. Krzyzanski W, Perez-Ruixo JJ, Vermeulen A (2008) Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells. J Pharmacokinet Pharmacodyn 35(3):349-377
54. Kusama S, Spratt JS Jr, Donegan WL, Watson FR, Cunningham C (1972) The gross rates of growth of human mammary cancer. Cancer 30:594-599
55. Levasseur LM, Slocum HK, Rustum YM, Greco WR (1998) Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 58:5749-5761
56. Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, Wild R, Lee FY (2005) Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol 56:455-464
57. Mager DE, Jusko WJ (2002) Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharm Res 19:1537-1543
58. Mager DE, Woo S, Jusko WJ (2009) Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24(1):16-24
59. Magni P, Simeoni M, Poggesi I, Rocchetti M, de Nicolao G (2006) A mathematical model to study the effects of drugs administration on tumor growth dynamics. Math Biosci 200:127-151
60. Mathon NF, Lloyd AC (2001) Milestones in cell division: Cell senescence and cancer. Nature Rev Cancer 1:203-213
61. Mayneord WV (1932) On the law of growth in Jensen's rat sarcoma. Am J Cancer 16:841-846
62. McDougall SR, Anderson AR, Chaplain MA (2006) Mathematical modelling of dynamic adaptive tumor-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol 241:564-589
63. Mould DR, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. Biodrugs 24:23-39
64. Mould DR, Sweeney K, Duffull SB, Neylon E, Hamlin P, Horwitz S, Sirotnak F, Fleisher M, Saunders ME, O'Connor OA (2009) A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther 86(2):190-196
65. Mukherjee A, Majumder D (2008) Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints. Biosystems 91:108-116
66. Peletier LA, Gabrielsson J (2009) Dynamics of target-mediated drug disposition. Eur J Pharm Sci 38(5):445-464
67. Quaranta V, Weaver AM, Cummings PT, Anderson ARA (2005) Mathematical modeling of cancer: the future of prognosis and treatment. Clin Chim Acta 357:173-179
68. Rabinowitz J, Davidov O (2008) The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 34(2):286-291
69. Ratain MJ, Eckhardt SG (2004) Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 22(22):4442-4445
70. Rew DA (2000a) Modelling in tumor biology part 1: modelling concepts and structures. Eur J Surg Oncol 26:87-94
71. Rew DA (2000b) Modelling in tumor biology part II: modelling cancer therapy. Eur J Surg Oncol 26:181-188
72. Rew DA, Wilson GD (2000a) Cell production rates in human tissues and tumors and their significance. Part 1: an introduction to the techniques of measurement and their limitations. Eur J Surg Oncol 26:227-238
73. Rew DA, Wilson GD (2000b) Cell production rates in human tissues and tumors and their significance. Part II: clinical data. Eur J Surg Oncol 26:405-417
74. Rocchetti M, Simeoni M, Pesenti E, de Nicolao G, Poggesi I (2007) Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 43:1862-1868
75. Saad ED, Katz A, Hoff PM, Buyse M (2010) Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 21:7-12
76. Santen G, Horrigan J, Danhof M, Della Pasqua O (2009) From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther 86(3):255-262
77. Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walker M, Cuzick J (2008) Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 99:1572-1578
78. Sidorov IA, Hirsch KS, Harley CB, Dimitrov DS (2003) Cancer treatment by telomerase inhibitors: predictions by a kinetic model. Math Biosci 181:209-221
79. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094-1101
80. Steel GG (1977) Growth kinetics of tumors: cell population kinetics in relation to the growth and treatment of cancer. Clarendon, Oxford
81. Steimer JL, Dahl SG, De Alwis DP, Gundert-Remy U, Karlsson MO, Martinkova J, Aarons L, Ahr HJ, Clairambault J, Freyer G, Friberg LE, Kern SE, Kopp-Schneider A, Ludwig WD, De Nicolao G, Rocchetti M, Troconiz IF (2010) Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics. Eur J Cancer 46:21-32
82. Swanson KR, Bridge C, Murray JD, Alvord EC Jr (2003) Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J Neurol Sci 216(1):1-10
83. Tan WY, Chen CW (1998) Stochastic modeling of carcinogenesis: some new insights. Math Comput Modelling 28(11):49-71
84. Tannock I (1986) Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat Biol 49:335-355
85. Ternant D, Paintaud G (2005) Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol There 5(Suppl 1):S37-S47
86. Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong PW, Goh BC, Holford NHG (2008) A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res 14(13):4213-4218
87. Tracqui P, Cruywagen GC, Woodward DE, Bartoo GT, Murray JD, Alvord EC Jr (1995) A mathematical model of glioma growth: the effect of chemotherapy on spatio-temporal growth. Cell Prolif 28:17-31
88. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2007) Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics.
89. van Kesteren Ch, Mathôt RA, Beijnen JH, Schellens JH (2003) Pharmacokinetic-pharmacodynamic guided trial design in oncology. Invest New Drugs 21(2):225-241
90. Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P (2000) Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 68 (6):677-687
91. Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, Gobburu J (2009) Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 86(2):167-174
92. Williamson MJ, Silva MD, Terkelsen J, Robertson R, Yu L, Xia C, Hatsis P, Bannerman B, Babcock T, Cao Y, Kupperman E (2009) The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol Cancer Ther 8:3234-3243
93. Wilson GD (1991) Assessment of human tumor proliferation using bromodeoxyuridine - current status. Acta Oncol 30:903-910
94. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T (2008) Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36(7):1267-1274
95. You B, Perrin P, Freyer G, Ruffion A, Tranchand B, Hénin E, Paparel P, Ribba B, Devonec M, Falandry C, Fournel C, Tod M, Girard P (2008a) Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Clin Biochem 41:785-795
96. You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, Souquet PJ, Court-Fortune I, Trillet-Lenoir V, Fournel C, Tod M, Freyer G (2008b) Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. Lung Cancer 62(2):261-272
97. You B, Girard P, Paparel P, Freyer G, Ruffion A, Charrié A, Hénin E, Tod M, Perrin P (2009) Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy. Prostate 69(12):1325-1333
98. You B, Pollet-Villard M, Fronton L, Labrousse C, Schott AM, Hajri T, Girard P, Freyer G, Tod M, Tranchand B, Colomban O, Ribba B, Raudrant D, Massardier J, Chabaud S, Golfier F (2010) Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol. doi:10.1093/annonc/mdq033
99. Zandvliet AS, Schellens JHM, Dittrich C, Wanders J, Beijnen JH, Huitema ADR (2008) Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol 66(4):485-497